Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has shown a positive financial trajectory, with a reported top-line revenue of $191.8 million for Q3 2025, reflecting a 10% quarter-over-quarter increase and a 5% year-over-year increase, surpassing market expectations. The company anticipates high-single digit unit growth for Baqsimi in 2025, driven by a successful sales collaboration and seasonal demand, along with strong performance from Primatene Mist that is expected to benefit from fall and winter usage. Furthermore, Amphastar projects a return to double-digit growth in 2026 despite current variations in the sales of glucagon and epinephrine products.

Bears say

Amphastar Pharmaceuticals Inc. is experiencing significant downward revisions in its sales forecasts, particularly for its iron sucrose and glucagon products, which are now projected to generate considerably lower revenues than initially anticipated due to increased market competition and supply challenges. The pharmaceutical company is facing a challenging competitive landscape, with glucagon sales expected to decline below $70 million as new competitors continue to enter the market, further impacting revenue projections. Additionally, expectations for a robust return to double-digit top-line growth in 2026 have been tempered, with prospects now leaning towards only moderate growth in the high-single digit to low-double digit range, raising concerns about the overall health of the company's future earnings prospects.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.